{"url_path":"/sec/sngx/8-k/2026-06-12/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/812796/0001104659-26-073430-index.html","accession_number":"0001104659-26-073430","cik":"0000812796","ticker":"SNGX","issuer_name":"SOLIGENIX, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/812796/0001104659-26-073430-index.html","primary_entity_key":"0000812796","primary_entity_name":"SOLIGENIX, INC."},"word_count":184,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n​\n\nAs previously disclosed, Richard C. Straube, MD, retired from his employment as Chief Medical Officer and Senior Vice President of Soligenix, Inc. (the “Company”) effective August 12, 2025 and entered into a one-year consulting agreement (the “Consulting Agreement”), pursuant to which Dr. Straube served as the Company’s Consulting Chief Medical Officer effective August 16, 2025. Under the Consulting Agreement, Dr. Straube served as an independent contractor and received an hourly consulting fee of $1,000 per hour for up to ten hours per month of consulting work.\n\n​\n\nOn June 11, 2026, in connection with the Company’s decision to terminate the HyBryte™ development program as described under Item 8.01 below, Dr. Straube ceased serving as the Company’s Consulting Chief Medical Officer.  The Company and Dr. Straube have agreed that Dr. Straube will continue to be available to consult with the Company on an as-needed, hourly basis. In the interim, Dr. Straube’s responsibilities will be transitioned to Dr. Christopher Pullion, the Company’s Medical Director.\n\n​"}